Adaptation of mesenchymal stromal cells to culture on collagen-based bioscaffold.
Ong HT., Vargas-Landin DB., Redmond SL., Neethling L., Rhodes DI., Dilley RJ.
Laboratory Study, published in J Mater Sci Mater Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Mater Sci Mater Med (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42262641
- DOI
- 10.1007/s10856-026-07069-4
Abstract (original English)
Decellularized tissue scaffolds may provide a substrate for cell delivery, yet their impact on stem cell function remains unclear. We evaluated a decellularized pericardium bioscaffold (CardioCel ® ) as a platform for mesenchymal stromal cells (MSC), testing whether it maintains multipotency without enforcing lineage commitment. Human adipose- and bone marrow-derived MSC adhered, proliferated, and differentiated under appropriate stimuli when cultured on the scaffold. Transcriptome analysis showed most genes retained their expression levels, with only 57 differentially expressed, mainly in pathways related to adhesion, oxygen response, and endogenous stimuli. Genes encoding regenerative paracrine factors were preserved, indicating that the scaffold provides a supportive but non-directive environment. These findings suggest MSC assays can serve as a screening approach to predict scaffold compatibility with endogenous progenitor cells, supporting the broader application of pericardium scaffolds in regenerative medicine.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.